Premium
Genmab AS (GE9)
TG
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-29 | Mr. Michael KavanaghSenior Director, Head of Strategic Engagement & Oncology Marketing and Non-Independent Director | -526,00 | 142,55k | Vente | 271,00 | 0,00 | -100,00% |
| 2026-04-01 | Dr. Judith V. KlimovskyExec. VP & Chief Development Officer | 4,74k | 1,30M | Derivative Exercise and Retained Stock | 273,16 | 15,56k | 43,86% |
| 2026-04-01 | Dr. Tahamtan AhmadiExec. VP, Chief Medical Officer & Head of Experimental Medicines | 5,19k | 1,42M | Derivative Exercise and Retained Stock | 273,16 | 10,05k | 106,66% |
| 2026-04-01 | Mr. Anthony PaganoExec. VP & CFO | 4,21k | 1,15M | Derivative Exercise and Retained Stock | 273,16 | 10,31k | 68,89% |
| 2026-04-01 | Dr. Jan G.J. van de WinkelCo-Founder, President & CEO | 439,00 | 119,92k | Derivative Exercise and Retained Stock | 273,16 | 659,94k | 0,07% |
| 2026-03-02 | Dr. Jan G.J. van de WinkelCo-Founder, President & CEO | 567,00 | 0,00 | Derivative Exercise and Retained Stock | - | 659,50k | 0,09% |
| 2026-03-02 | Mr. Anthony PaganoExec. VP & CFO | 200,00 | 0,00 | Derivative Exercise and Retained Stock | - | 6,11k | 3,39% |
| 2026-03-02 | Mr. Martin SchultzSenior Director, Head of Development Business Partnership & Strategy and Director | 197,00 | 0,00 | Derivative Exercise and Retained Stock | - | 865,00 | 29,49% |
| 2026-03-02 | Dr. Mijke ZachariasseVP, Head of Antibody Research Materials & Director | 64,00 | 0,00 | Derivative Exercise and Retained Stock | - | 851,00 | 8,13% |
| 2026-03-02 | Mr. Michael KavanaghSenior Director, Head of Strategic Engagement & Oncology Marketing and Non-Independent Director | 305,00 | 0,00 | Derivative Exercise and Retained Stock | - | 526,00 | 138,01% |
| 2026-02-19 | Mr. Anthony PaganoExec. VP & CFO | -1,10k | 313,50k | Vente | 285,00 | 5,91k | -15,70% |
| 2025-12-01 | Dr. Anders Gersel PedersenNon-Independent Director | 189,00 | 60,10 | Derivative Exercise and Retained Stock | 0,32 | 7,71k | 2,51% |
| 2025-12-01 | Ms. Elizabeth G. O'FarrellIndependent Director | 189,00 | 60,10 | Derivative Exercise and Retained Stock | 0,32 | 1,89k | 11,14% |
| 2025-12-01 | Ms. Deirdre P. ConnellyIndependent Chairman of the Board | 378,00 | 120,19 | Derivative Exercise and Retained Stock | 0,32 | 6,58k | 6,09% |
| 2025-12-01 | Mr. Rolf Karl-Heinz HoffmannIndependent Director | 189,00 | 60,10 | Derivative Exercise and Retained Stock | 0,32 | 3,78k | 5,26% |
| 2025-12-01 | Ms. Pernille ErenbjergIndependent Deputy Chairman | 283,00 | 89,98 | Derivative Exercise and Retained Stock | 0,32 | 5,47k | 5,46% |
| 2025-12-01 | Dr. Paolo PaolettiIndependent Director | 189,00 | 60,10 | Derivative Exercise and Retained Stock | 0,32 | 2,51k | 8,16% |
| 2025-12-01 | Mr. Martin SchultzSenior Director, Head of Development Business Partnership & Strategy and Director | 189,00 | 60,10 | Derivative Exercise and Retained Stock | 0,32 | 400,00 | 89,57% |
| 2025-12-01 | Dr. Mijke ZachariasseVP, Head of Antibody Research Materials & Director | 189,00 | 60,10 | Derivative Exercise and Retained Stock | 0,32 | 690,00 | 37,72% |
| 2025-11-19 | Mr. Martin SchultzSenior Director, Head of Development Business Partnership & Strategy and Director | -175,00 | 52,99k | Vente | 302,78 | 211,00 | -45,34% |
| 2025-09-09 | Dr. Jan G.J. van de WinkelCo-Founder, President & CEO | 23,27k | 3,75M | Derivative Exercise and Retained Stock | 160,99 | 658,93k | 3,66% |
| 2025-06-17 | Dr. Mijke ZachariasseVP, Head of Antibody Research Materials & Director | -250,00 | 57,34k | Vente | 229,37 | 501,00 | -33,29% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
